Clinical Trial

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

Study acronym: TRANS-SWITCH
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-07; most recent amendment 2025-09-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT06967753
Lead Sponsor UBATEC
Collaborators: ViiV Healthcare, Hospital Fernandez
Conditions HIV, HIV-1
Enrollment 50 participants
Start Date 2025-07-31
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-12